These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25292178)

  • 1. Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
    Somyajit K; Mishra A; Jameei A; Nagaraju G
    Carcinogenesis; 2015 Jan; 36(1):13-24. PubMed ID: 25292178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
    Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
    Soni A; Siemann M; Pantelias GE; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining.
    Mansour WY; Borgmann K; Petersen C; Dikomey E; Dahm-Daphi J
    DNA Repair (Amst); 2013 Dec; 12(12):1134-42. PubMed ID: 24210699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
    Du W; Amarachintha S; Wilson AF; Pang Q
    Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
    Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
    Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination.
    Mateos-Gomez PA; Gong F; Nair N; Miller KM; Lazzerini-Denchi E; Sfeir A
    Nature; 2015 Feb; 518(7538):254-7. PubMed ID: 25642960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.
    Howard SM; Yanez DA; Stark JM
    PLoS Genet; 2015 Jan; 11(1):e1004943. PubMed ID: 25629353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
    Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
    Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
    Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
    J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    Gaziev AI
    Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of alternative end joining by the chromatin remodeler p400 ATPase.
    Taty-Taty GC; Chailleux C; Quaranta M; So A; Guirouilh-Barbat J; Lopez BS; Bertrand P; Trouche D; Canitrot Y
    Nucleic Acids Res; 2016 Feb; 44(4):1657-68. PubMed ID: 26578561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair.
    Luoto KR; Meng AX; Wasylishen AR; Zhao H; Coackley CL; Penn LZ; Bristow RG
    Cancer Res; 2010 Nov; 70(21):8748-59. PubMed ID: 20940401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.
    Luijsterburg MS; de Krijger I; Wiegant WW; Shah RG; Smeenk G; de Groot AJL; Pines A; Vertegaal ACO; Jacobs JJL; Shah GM; van Attikum H
    Mol Cell; 2016 Feb; 61(4):547-562. PubMed ID: 26895424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.
    Patel AG; Sarkaria JN; Kaufmann SH
    Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3406-11. PubMed ID: 21300883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
    Wang X; Liu L; Montagna C; Ried T; Deng CX
    Cell Death Differ; 2007 May; 14(5):924-31. PubMed ID: 17318223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.
    Gaymes TJ; Shall S; Farzaneh F; Mufti GJ
    Haematologica; 2008 Dec; 93(12):1886-9. PubMed ID: 18838476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
    Newman EA; Lu F; Bashllari D; Wang L; Opipari AW; Castle VP
    Mol Cancer Res; 2015 Mar; 13(3):470-82. PubMed ID: 25563294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
    Naipal KA; Verkaik NS; Ameziane N; van Deurzen CH; Ter Brugge P; Meijers M; Sieuwerts AM; Martens JW; O'Connor MJ; Vrieling H; Hoeijmakers JH; Jonkers J; Kanaar R; de Winter JP; Vreeswijk MP; Jager A; van Gent DC
    Clin Cancer Res; 2014 Sep; 20(18):4816-26. PubMed ID: 24963051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.